HUE056414T2 - Triptofán-2,3-dioxigenázt vagy annak fragmentumait tartalmazó vakcinakészítmények - Google Patents
Triptofán-2,3-dioxigenázt vagy annak fragmentumait tartalmazó vakcinakészítményekInfo
- Publication number
- HUE056414T2 HUE056414T2 HUE15774851A HUE15774851A HUE056414T2 HU E056414 T2 HUE056414 T2 HU E056414T2 HU E15774851 A HUE15774851 A HU E15774851A HU E15774851 A HUE15774851 A HU E15774851A HU E056414 T2 HUE056414 T2 HU E056414T2
- Authority
- HU
- Hungary
- Prior art keywords
- dioxygenase
- tryptophan
- fragments
- vaccine compositions
- vaccine
- Prior art date
Links
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 title 1
- 102000057288 Tryptophan 2,3-dioxygenases Human genes 0.000 title 1
- 239000012634 fragment Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4244—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
- C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
- C12Y113/11011—Tryptophan 2,3-dioxygenase (1.13.11.11), i.e. indolamine 2,3-dioxygenase 2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/90241—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Rehabilitation Therapy (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201470571 | 2014-09-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE056414T2 true HUE056414T2 (hu) | 2022-02-28 |
Family
ID=51661826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE15774851A HUE056414T2 (hu) | 2014-09-17 | 2015-09-15 | Triptofán-2,3-dioxigenázt vagy annak fragmentumait tartalmazó vakcinakészítmények |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10736950B2 (enExample) |
| EP (2) | EP3193917B9 (enExample) |
| JP (1) | JP6811710B2 (enExample) |
| CN (1) | CN106999557B (enExample) |
| AU (1) | AU2015317446B2 (enExample) |
| CA (1) | CA2959197C (enExample) |
| CY (1) | CY1124738T1 (enExample) |
| DK (1) | DK3193917T3 (enExample) |
| ES (1) | ES2891902T3 (enExample) |
| HR (1) | HRP20211540T2 (enExample) |
| HU (1) | HUE056414T2 (enExample) |
| IL (1) | IL251101B (enExample) |
| LT (1) | LT3193917T (enExample) |
| PL (1) | PL3193917T3 (enExample) |
| PT (1) | PT3193917T (enExample) |
| SI (1) | SI3193917T1 (enExample) |
| WO (1) | WO2016041560A1 (enExample) |
| ZA (1) | ZA201701179B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110628736B (zh) * | 2019-10-09 | 2021-05-11 | 扬州大学 | 色氨酸2,3双加氧酶突变体及其制备方法和应用 |
| CN111012919B (zh) * | 2019-12-23 | 2021-06-01 | 山东大学 | 聚乙二醇化的icd诱导剂-ido抑制剂纳米缀合物及制备方法与应用 |
| CN111803635B (zh) * | 2020-06-17 | 2023-03-14 | 中国医学科学院基础医学研究所 | 小分子抑制剂在治疗呼吸道病毒性肺炎上的应用 |
| WO2022245841A1 (en) * | 2021-05-17 | 2022-11-24 | Wisconsin Alumni Research Foundation | Synthetic protein for inducing immune tolerance |
| US20250327041A1 (en) | 2022-02-24 | 2025-10-23 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US58767A (en) | 1866-10-16 | John brougjbton | ||
| US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
| US6096313A (en) | 1996-02-09 | 2000-08-01 | Ludwig Institute For Cancer Research | Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant |
| US5840839A (en) * | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
| EP1892306A3 (en) * | 2003-10-06 | 2008-06-11 | Bayer HealthCare AG | Methods and kits for investigating cancer |
| DE102004039196B4 (de) * | 2004-08-12 | 2008-07-31 | Dr.Kamprad Kg | Neue Formulierung für L-Tryptophan |
| US20110159017A1 (en) * | 2008-04-11 | 2011-06-30 | Ludwig Institute For Cancer Research Ltd. | Trytophan catabolism in cancer treatment and diagnosis |
| EP3915570A1 (en) * | 2008-04-17 | 2021-12-01 | IO BIOTECH ApS | Indoleamine 2, 3-dioxygenase based immunotherapy |
| HUE049886T2 (hu) * | 2010-05-14 | 2020-10-28 | Massachusetts Gen Hospital | Tumorspecifikus neoantigéneket tartalmazó készítmények, tumorok kezelésében történõ alkalmazásra |
| LT2768524T (lt) | 2011-10-17 | 2022-07-25 | Io Biotech Aps | Pd-l1 grindžiama imunoterapija |
| GB201120860D0 (en) * | 2011-12-05 | 2012-01-18 | Cambridge Entpr Ltd | Cancer immunotherapy |
-
2015
- 2015-09-15 PT PT157748518T patent/PT3193917T/pt unknown
- 2015-09-15 HR HRP20211540TT patent/HRP20211540T2/hr unknown
- 2015-09-15 ES ES15774851T patent/ES2891902T3/es active Active
- 2015-09-15 CA CA2959197A patent/CA2959197C/en active Active
- 2015-09-15 EP EP15774851.8A patent/EP3193917B9/en active Active
- 2015-09-15 EP EP21176526.8A patent/EP3919074A1/en active Pending
- 2015-09-15 WO PCT/DK2015/050274 patent/WO2016041560A1/en not_active Ceased
- 2015-09-15 SI SI201531744T patent/SI3193917T1/sl unknown
- 2015-09-15 LT LTEPPCT/DK2015/050274T patent/LT3193917T/lt unknown
- 2015-09-15 CN CN201580050212.3A patent/CN106999557B/zh active Active
- 2015-09-15 HU HUE15774851A patent/HUE056414T2/hu unknown
- 2015-09-15 JP JP2017514626A patent/JP6811710B2/ja active Active
- 2015-09-15 DK DK15774851.8T patent/DK3193917T3/da active
- 2015-09-15 AU AU2015317446A patent/AU2015317446B2/en active Active
- 2015-09-15 US US15/509,443 patent/US10736950B2/en active Active
- 2015-09-15 PL PL15774851T patent/PL3193917T3/pl unknown
-
2017
- 2017-02-16 ZA ZA2017/01179A patent/ZA201701179B/en unknown
- 2017-03-12 IL IL251101A patent/IL251101B/en active IP Right Grant
-
2020
- 2020-07-07 US US16/922,604 patent/US11878053B2/en active Active
-
2021
- 2021-11-16 CY CY20211100992T patent/CY1124738T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US10736950B2 (en) | 2020-08-11 |
| ZA201701179B (en) | 2021-05-26 |
| ES2891902T3 (es) | 2022-01-31 |
| JP6811710B2 (ja) | 2021-01-20 |
| US20210023191A1 (en) | 2021-01-28 |
| AU2015317446B2 (en) | 2020-08-13 |
| EP3919074A1 (en) | 2021-12-08 |
| HRP20211540T1 (hr) | 2021-12-24 |
| IL251101A0 (en) | 2017-04-30 |
| SI3193917T1 (sl) | 2022-02-28 |
| DK3193917T3 (da) | 2021-10-04 |
| HRP20211540T2 (hr) | 2022-05-13 |
| JP2017533182A (ja) | 2017-11-09 |
| EP3193917A1 (en) | 2017-07-26 |
| CY1124738T1 (el) | 2022-07-22 |
| CA2959197C (en) | 2023-03-14 |
| PT3193917T (pt) | 2021-10-20 |
| ES2891902T9 (es) | 2022-03-02 |
| CN106999557A (zh) | 2017-08-01 |
| AU2015317446A1 (en) | 2017-04-20 |
| US11878053B2 (en) | 2024-01-23 |
| US20170239337A1 (en) | 2017-08-24 |
| WO2016041560A1 (en) | 2016-03-24 |
| LT3193917T (lt) | 2021-11-25 |
| CA2959197A1 (en) | 2016-03-24 |
| IL251101B (en) | 2021-05-31 |
| EP3193917B1 (en) | 2021-08-18 |
| CN106999557B (zh) | 2021-04-20 |
| EP3193917B9 (en) | 2022-02-16 |
| PL3193917T3 (pl) | 2022-01-17 |
| NZ730708A (en) | 2024-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3393510T3 (da) | Zikavirusvaccine | |
| DK3151672T3 (da) | Forbedrede t-celle-sammensætninger | |
| BR112016023628A2 (pt) | composições farmacêuticas. | |
| DK3104718T3 (da) | Tobaksholdig gelsammensætning | |
| DK3089741T3 (da) | Farmaceutiske sammensætninger omfattende azd9291 | |
| DK3130649T3 (da) | Haloolefin-baseret sammensætning | |
| DK3215173T3 (da) | Glycopeptidsammensætninger | |
| FR3024363B1 (fr) | Composition thermogelifiable | |
| DK3209323T3 (da) | Forbedret koaguleringssammensætning | |
| FR3024324B3 (fr) | Souffleur | |
| DK3129007T3 (da) | Vaccinesammensætninger | |
| EP3560512A4 (en) | COMPOSITION OF VACCINE AGAINST ZONA | |
| CL2017000639A1 (es) | Composición | |
| EA202092926A3 (ru) | Лиофилизированные составы, содержащие фактор ix | |
| IL251101B (en) | Vaccine compounds comprising tryptophan 3,2-dioxygenase or fragments thereof | |
| EP3236746C0 (en) | COMPOSITION | |
| DK3200827T3 (da) | Sammensætninger | |
| DK3155004T3 (da) | Vaccine til immunkompromitterede værter | |
| EP3325002C0 (en) | COMBINED THERAPEUTIC COMPOSITIONS | |
| DK3217964T3 (da) | Sammensætning | |
| DK3089740T3 (da) | Farmaceutisk sammensætning | |
| FR3019552B1 (fr) | Composition filmogene | |
| LT3188755T (lt) | Vakcina | |
| TH1501004575A (th) | พอซีนพาโวไวรัส 5b, วิธีการใช้และวัคซีน | |
| TH1601003236A (th) | วัคซีนสุกร |